StockNews.AI
EXEL
StockNews.AI
2 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL

1. Investigation into EXEL for potential securities fraud has been initiated. 2. EXEL's Q2 2025 revenue fell 2% below estimates at $531.3 million. 3. Decision made not to progress phase 3 STELLAR-305 trial due to competition. 4. EXEL's stock dropped 16.78% following the announcement news.

4m saved
Insight
Article

FAQ

Why Bearish?

The ongoing investigation and poor financial results suggest increased risk for EXEL, similar to past cases like Valeant Pharmaceuticals, which suffered massive stock depreciation following allegations.

How important is it?

Continued investigations and revenue underperformance often lead to decreased investor confidence, impacting stock prices significantly.

Why Short Term?

The immediate market reaction to the investigation and missed revenue targets likely impacts EXEL's price in the near term, as seen in similar situations like with Tesla's controversies.

Related Companies

TSLAVRXJAZZ
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Exelixis and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On July 28, 2025, Exelixis issued a press release “report[ing] financial results for the second quarter of 2025” and “provid[ing] an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones.”  Among other items, Exelixis reported that net product revenues for cabozantinib were approximately 2% below the consensus estimate of $531.3 million.  Exelixis also disclosed that “[b]ased on our evaluation of emerging data from the phase 2 portion of the STELLAR-305 study in advanced squamous cell carcinoma of the head and neck, emerging competition in this indication and assessment of other potentially larger commercial opportunities, we have made the decision not to proceed to the phase 3 portion of the trial.”    On this news, Exelixis’s stock price fell $7.45 per share, or 16.78%, to close at $36.94 per share on July 29, 2025.  Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.    CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News